Almirall, S.A. (0O9B.IL)

8,64 +0,02 (+0,23%) Alla chiusura: 04:51PM BST

Almirall, S.A.

Ronda Del General Miter, 151
Barcelona 08022
Spain
34 93 291 30 00
https://www.almirall.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 1.876

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Carlos Gallardo Piqué	CEO & Chairman	50k	N/D	1972
Mr. Michael McClellan	Exec. VP of Fin., CFO & Member of Management Board	N/D	N/D	1972
Mr. Eloi Crespo Cervera	Sr. VP of Industrial Operations & Member of Management Board	N/D	N/D	N/D
Mr. Jordi Sabé Richer	Sr. VP of Corp. Devel. & Member of Management Board	N/D	N/D	N/D
Mr. Esteve Conesa Panicot	Sr. VP of HR & Member of Management Board	N/D	N/D	N/D
Dr. Volker Koscielny	Chief Medical Officer & Member of Management Board	N/D	N/D	N/D
Mr. Pablo Alvarez	Member of Management Board, Pres of Almirall US & GM of Almirall US	N/D	N/D	N/D
Dr. Karl Ziegelbauer	Exec. VP of R&D, CSO and Member of Management Board	N/D	N/D	N/D
Mr. Paolo Cionini	Chief Commercial Officer Europe & International and Member of Management Board	N/D	N/D	N/D
Ms. Isabel Gomes	Gen. Counsel & Member of Management Board	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2015 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in EUR.

Descrizione

Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.

Governance aziendale

L'ISS Governance QualityScore di Almirall, S.A. al 1 ottobre 2023 è 4. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 4; diritti degli azionisti: 3; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.